BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11325832)

  • 1. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex.
    Liu H; Lee ES; Deb Los Reyes A; Zapf JW; Jordan VC
    Cancer Res; 2001 May; 61(9):3632-9. PubMed ID: 11325832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
    Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
    J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
    Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
    Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12.
    Pearce ST; Liu H; Jordan VC
    J Biol Chem; 2003 Feb; 278(9):7630-8. PubMed ID: 12496244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiles with activation of the estrogen receptor alpha-selective estrogen receptor modulator complex in breast cancer cells expressing wild-type estrogen receptor.
    Levenson AS; Svoboda KM; Pease KM; Kaiser SA; Chen B; Simons LA; Jovanovic BD; Dyck PA; Jordan VC
    Cancer Res; 2002 Aug; 62(15):4419-26. PubMed ID: 12154049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
    Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
    Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
    Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor alpha mediated induction of the transforming growth factor alpha gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells.
    MacGregor Schafer J; Liu H; Levenson AS; Horiguchi J; Chen Z; Jordan VC
    J Steroid Biochem Mol Biol; 2001 Jul; 78(1):41-50. PubMed ID: 11530283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nongenomic activity and subsequent c-fos induction by estrogen receptor ligands are not sufficient to promote deoxyribonucleic acid synthesis in human endometrial adenocarcinoma cells.
    Singleton DW; Feng Y; Burd CJ; Khan SA
    Endocrinology; 2003 Jan; 144(1):121-8. PubMed ID: 12488337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants for the tissue specificity of SERMs.
    Shang Y; Brown M
    Science; 2002 Mar; 295(5564):2465-8. PubMed ID: 11923541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor.
    Levenson AS; Jordan VC
    Cancer Res; 1998 May; 58(9):1872-5. PubMed ID: 9581827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Point mutation of estrogen receptor (ER) in the ligand-binding domain changes the pharmacology of antiestrogens in ER-negative breast cancer cells stably expressing complementary DNAs for ER.
    Jiang SY; Langan-Fahey SM; Stella AL; McCague R; Jordan VC
    Mol Endocrinol; 1992 Dec; 6(12):2167-74. PubMed ID: 1491696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
    Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
    J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.
    Demirpence E; Semlali A; Oliva J; Balaguer P; Badia E; Duchesne MJ; Nicolas JC; Pons M
    Cancer Res; 2002 Nov; 62(22):6519-28. PubMed ID: 12438246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells.
    Tonetti DA; Rubenstein R; DeLeon M; Zhao H; Pappas SG; Bentrem DJ; Chen B; Constantinou A; Craig Jordan V
    J Steroid Biochem Mol Biol; 2003 Oct; 87(1):47-55. PubMed ID: 14630090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17 beta-estradiol- and 4-hydroxytamoxifen-induced transactivation in breast, endometrial and liver cancer cells is dependent on ER-subtype, cell and promoter context.
    Castro-Rivera E; Safe S
    J Steroid Biochem Mol Biol; 2003 Jan; 84(1):23-31. PubMed ID: 12648521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha.
    Dayan G; Lupien M; Auger A; Anghel SI; Rocha W; Croisetière S; Katzenellenbogen JA; Mader S
    Mol Pharmacol; 2006 Aug; 70(2):579-88. PubMed ID: 16679488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.